Pink Sheet
Scrip
Medtech Insight
HBW Insight
Generics Bulletin
In Vivo
Spotlight
GLP-1s
Interviews
FDA
Strategy
Generics
Biosimilars
Value Added Medicines
Business
Deals
Earnings
Manufacturing
Policy & Regulation
Regulatory Landscape
Drug Pricing
IP & Litigation
Tools & Trackers
What's Next?
Who's Hired?
UK Pricing Tracker
Company Rankings
Podcasts
Conference Coverage
Partner Insights
Generics Bulletin Perspectives
Exploring market-shifting topics for the off-patent sector.
View
In Vivo
Generics Bulletin
HBW Insight
Medtech Insight
Pink Sheet
Scrip
Viatris Hikes Guidance With The Wind On Its Back At Halfway Stage
Low-End Guidance Jumps From $17.2bn To $17.5bn Total For 2021
Aug 11 2021
•
By
Dean Rudge
Several factors led Viatris to raise its guidance for 2021 • Source: Alamy
More from Earnings
More from Business